Dr. Ascheim most recently served as CMO of StrideBio, a gene therapy company, where she led all clinical initiatives, including clinical trials for the company’s therapeutic programs, according to a Jan. 3 news release from the company. She has also served as president of clinical and product development consulting firm d2a Ltd.
Dr. Ascheim has more than 20 years of experience in academia, most recently as a professor of health policy and medicine at the Icahn School of Medicine at Mount Sinai in New York City. She was also on the faculty of Columbia University in New York City for 14 years.
Rejuvenate Bio is a San-Diego based company focusing on reversing aging and eliminating age-related diseases using gene therapy, proprietary targets and other tools. It is a spinoff from the Wyss Institute for Biologically Inspired Engineering at Cambridge, Mass.-based Harvard University, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.